drugset / Trial / NCT01156389
Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine any drug interaction between the antimalarial Pyramax (pyronaridine artesunate) and the protease inhibitor ritonavir in healthy subjects. The secondary objective of the study is to assess further the safety of Pyramax in this setting.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-08
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |
| Comparator | pyronaridine/artesunate | Unknown | 60 mg | — |
| Comparator | pyronaridine/artesunate | Unknown | 180 mg | — |